Back to Research

Organization profile

Gibela Therapeutics

Gibela Therapeutics GmbH is an RNA-therapeutics startup, spun off from CIC bioGUNE, focused on the research, discovery, development, manufacturing, and commercialization of pharmaceutical products. These products primarily target mitochondrial dysfunction and endoplasmic reticulum (ER) stress to treat various diseases, including liver diseases (alcoholic liver disease, non-alcoholic fatty liver disease), lung fibrosis, and kidney fibrosis.

Basel, SwitzerlandFounded 2023

Overview

Gibela Therapeutics GmbH is an RNA-therapeutics startup, spun off from CIC bioGUNE, focused on the research, discovery, development, manufacturing, and commercialization of pharmaceutical products. These products primarily target mitochondrial dysfunction and endoplasmic reticulum (ER) stress to treat various diseases, including liver diseases (alcoholic liver disease, non-alcoholic fatty liver disease), lung fibrosis, and kidney fibrosis.

Unlock the full profileGet the complete company dossier

This public view only shows an extract. Open the full profile to access the complete company intelligence record, including the full write-up and structured research details.

Desktop only

Research is currently available on desktop only.

The Research module is designed for larger screens. Please reopen it on a desktop or laptop to use the screener, filters, detail pages, and admin tools.